This mechanistic insight provides a promising foundation for targeting non-coding RNAs, such as LINCMD1, to correct the abnormal activation of the Wnt/β-Catenin pathway, and as a potential therapeutic target for leiomyomas. The gene discussed is LINCMD1; the disease is leiomyoma.